Overview

A Phase II Dose Response Study in Japan in Chronic Hepatitis B

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA levels by PCR (log10 copies/mL) at Week 22
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Entecavir